Cited by 41Hereditary Neurological DisordersPeripheral Neuropathies and DisordersNeurofibromatosis and Schwannoma Cases

Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients

Open access
Lee, Sooyeon, Bazick, Hannah, Chittoor-Vinod, Vinita, Al Salihi, Mohammed Omar, Xia, Guangbin, Notterpek, Lucia·2018·The American Journal of Pathology

Abstract

A common form of hereditary autosomal dominant demyelinating neuropathy known as Charcot-Marie-Tooth disease type 1A (CMT1A) is linked with duplication of the peripheral myelin protein 22 (PMP22) gene. Although studies from animal models have led to better understanding of the pathobiology of these neuropathies, there continues to be a gap in the translation of findings from rodents to humans. Because PMP22 was originally identified in fibroblasts as growth arrest specific gene 3 (gas3) and is expressed broadly in the body, it was tested whether skin cells from neuropathic patients would display the cellular pathology observed in Schwann cells from rodent models. Dermal fibroblasts from two CMT1A pedigrees with confirmed PMP22 gene duplication were studied. Samples from age-matched non-neuropathic individuals were used as controls. CMT1A patient-derived cultures contain approximately 1.5-fold elevated levels of PMP22 mRNA, exhibit reduced mitotic potential, and display intracellular protein aggregates as compared to cells from unaffected individuals. The presence of cytosolic PMP22 coincides with a decrease in proteasome activity and an increase in autophagy-lysosomal proteins, including LC3-II and LAMP1. These results indicate that the abnormalities in the subcellular processing of excess PMP22 elicit a detectable response in human CMT1A fibroblasts, a phenotype that resembles Schwann cells from neuropathic mice. These findings support the use of human CMT1A fibroblasts as a platform for therapy testing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2017.10.021

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher JUN/c-Jun in CMT1A may be part of a compensatory, neuroprotective response to the pathogenic effects of the PMP22 duplication.

    “which may be part of a compensatory, neuroprotective response to the pathogenic effects of the PMP22 duplication [467–469].”
  • In CMT1A, elevated Schwann cell autophagy is associated with higher levels of JUN/c-Jun.

    “and associated with higher levels of JUN/c-Jun,”
  • In Charcot-Marie-Tooth type 1A caused by duplication of PMP22, Schwann cell autophagy is aberrantly elevated.

    “in Charcot-Marie-Tooth (CMT) type 1A caused by duplication of PMP22 (peripheral myelin protein 22), Schwann cell autophagy is aberrantly elevated”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lee, S., Bazick, H., Chittoor-Vinod, V., Al Salihi, M. O., Xia, G., & Notterpek, L.
Affiliations
  • University of Florida (US)
  • University of Florida Health (US)
Corresponding author
Notterpek, Lucia
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2018-03
Volume
188
Issue
3
Pages
728-738
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2773809639
Cited by
41
References
51
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 10 · 2020: 7 · 2019: 4 · 2018: 2
FWCI
1.74
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
NIH (NS041012)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
  • Health Sciences › Medicine › Neurology › Neurofibromatosis and Schwannoma Cases
Keywords
Charcot-Marie-Tooth disease type 1A, peripheral myelin protein 22, PMP22 gene duplication, dermal fibroblasts, demyelinating neuropathy, proteasome impairment, protein aggregates, autophagy-lysosome pathway, LC3-II, LAMP1, Schwann cells
MeSH terms
Adolescent, Adult, Charcot-Marie-Tooth Disease, Fibroblasts, Humans, Middle Aged, Myelin Proteins, Skin, Gene Duplication, Proteasome Endopeptidase Complex, Cell Proliferation, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review